Efficacy and safety of tocilizumab in adult-onset Still's disease: Real-life experience from the international AIDA registry.
暂无分享,去创建一个
P. Sfikakis | F. Ciccia | R. Giacomelli | M. Govoni | E. Bartoloni | A. Vitale | Claudia Fabiani | G. Emmi | G. Lopalco | B. Frediani | F. Iannone | D. Rigante | L. Cantarini | S. Gentileschi | F. Cardinale | P. Ruscitti | P. Cipriani | M. Tektonidou | G. Ragab | P. Sfriso | G. Sebastiani | A. Balistreri | K. Laskari | M. Hussein | M. Maggio | A. Lewandowska-Polak | C. Lomater | A. Marino | E. Więsik-Szewczyk | J. Makowska | C. Gaggiano | F. La Torre | J. Sota | A. Olivieri | A. Tufan | Francesca Della Casa | M. Hegazy | E. Giudice | R. Pereira | O. Brzezińska | A. Opinc | M. Dagostin | M. Tarsia | A. Maier | H. F. Giordano | Rossana Nuzzolese | I. P. Antonelli | I. D. Cola | Francesca Ruffili | Riza Kan Kardas | Parretti Veronica | Gaafar Ragab | Ewa Więsik-Szewczyk
[1] B. Ogunjimi,et al. Development and Implementation of the AIDA International Registry for Patients With Still's Disease , 2022, Frontiers in Medicine.
[2] A. Doria,et al. Progress in Biological Therapies for Adult-Onset Still’s Disease , 2022, Biologics : targets & therapy.
[3] C. Masciocchi,et al. The joint involvement in adult onset Still's disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile , 2021, Scientific Reports.
[4] P. Sfikakis,et al. Outcome of refractory to conventional and/or biologic treatment adult Still's disease following canakinumab treatment: Countrywide data in 50 patients. , 2020, Seminars in arthritis and rheumatism.
[5] M. Özgen,et al. Adult‐onset still’s disease and treatment results with tocilizumab , 2020, International journal of clinical practice.
[6] A. Vitale,et al. Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease , 2020, Mediators of inflammation.
[7] K. Uehara,et al. Reintroduction of tocilizumab elicited macrophage activation syndrome in a patient with adult-onset Still’s disease with a previous successful tocilizumab treatment , 2020, Modern rheumatology case reports.
[8] B. Anić,et al. Treatment of refractory adult onset Still’s disease with tocilizumab—a single centre experience and literature review , 2020, Rheumatology International.
[9] R. De Giorgio,et al. The reduction of concomitant glucocorticoids dosage following treatment with IL-1 receptor antagonist in adult onset Still’s disease. A systematic review and meta-analysis of observational studies , 2020, Therapeutic advances in musculoskeletal disease.
[10] C. Campochiaro,et al. The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature. , 2020, Clinical and experimental rheumatology.
[11] T. Barnetche,et al. Adult-onset Still’s disease biological treatment strategy may depend on the phenotypic dichotomy , 2019, Arthritis Research & Therapy.
[12] R. Cimaz,et al. Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis , 2019, Front. Pharmacol..
[13] Yoshiya Tanaka,et al. Tocilizumab in patients with adult-onset still’s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial , 2018, Annals of the rheumatic diseases.
[14] E. Feist,et al. Mechanisms, biomarkers and targets for adult-onset Still’s disease , 2018, Nature Reviews Rheumatology.
[15] Y. Shoenfeld,et al. A comprehensive review on adult onset Still's disease. , 2018, Journal of autoimmunity.
[16] D. Foell,et al. IL-6 blockade in systemic juvenile idiopathic arthritis – achievement of inactive disease and remission (data from the German AID-registry) , 2018, Pediatric Rheumatology.
[17] Jiajia Yang,et al. Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still’s disease: A meta-analysis , 2018, Modern rheumatology.
[18] Kazuhiko Yamamoto,et al. Macrophage activation syndrome associated with tocilizumab treatment in adult-onset Still’s disease , 2017, Modern rheumatology.
[19] M. Kawano,et al. Cytokine profile in adult-onset Still's disease: Comparison with systemic juvenile idiopathic arthritis. , 2016, Clinical immunology.
[20] D. Solmaz,et al. Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: Data from a large multicenter cohort. , 2016, Journal of autoimmunity.
[21] T. Kano,et al. Successful tocilizumab therapy in seven patients with refractory adult-onset Still's disease , 2016, Modern rheumatology.
[22] P. Sève,et al. Adult-onset Still's disease. , 2014, Autoimmunity reviews.
[23] S. Castañeda,et al. Efficacy of Tocilizumab in Conventional Treatment–Refractory Adult‐Onset Still's Disease: Multicenter Retrospective Open‐Label Study of Thirty‐Four Patients , 2014, Arthritis & rheumatology.
[24] P. Nigrovic. Review: Is There a Window of Opportunity for Treatment of Systemic Juvenile Idiopathic Arthritis? , 2014, Arthritis & rheumatology.
[25] J. Ablin,et al. Tocilizumab in Adult-onset Still’s Disease: the Israeli Experience , 2014, The Journal of Rheumatology.
[26] R. Giacomelli,et al. Tocilizumab for the treatment of adult-onset Still’s disease: results from a case series , 2013, Clinical Rheumatology.
[27] C. Wouters,et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. , 2012, The New England journal of medicine.
[28] H. Kautiainen,et al. Beneficial Effect of Interleukin 1 Inhibition with Anakinra in Adult-onset Still’s Disease. An Open, Randomized, Multicenter Study , 2012, The Journal of Rheumatology.
[29] A. Tzioufas,et al. Efficacy and long-term follow-up of IL-1R inhibitor anakinra in adults with Still's disease: a case-series study , 2011, Arthritis research & therapy.
[30] A. Mimori,et al. Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome , 2011, Modern rheumatology.
[31] J. Sibilia,et al. Tocilizumab in refractory adult Still's disease , 2011, Arthritis care & research.
[32] T. Kishimoto,et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial , 2008, The Lancet.
[33] T. Hsieh,et al. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. , 2004, The Journal of rheumatology.
[34] J. Volanakis,et al. Testosterone and IL-6 requirements for human C-reactive protein gene expression in transgenic mice. , 1998, Journal of immunology.
[35] M. Akizuki,et al. Preliminary criteria for classification of adult Still's disease. , 1992, The Journal of rheumatology.
[36] J. Esdaile,et al. Adult Still's Disease: Manifestations, Disease Course, and Outcome in 62 Patients , 1991, Medicine.